ORKA (Oruka Therapeutics) Common Stock : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Common Stock?

Oruka Therapeutics's quarterly common stock stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).

Oruka Therapeutics's annual common stock stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.04 Mil).

Oruka Therapeutics Common Stock Historical Data

The historical data trend for Oruka Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Common Stock Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Common Stock

0.04

Oruka Therapeutics Semi-Annual Data
	Mar24
Common Stock	-

Oruka Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.